strontium ranelate Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA).   Wikipedia

Chemistry

  • SMILES: [Sr+2].[Sr+2].[O-]C(=O)CN(CC(=O)[O-])c1sc(C(=O)[O-])c(CC(=O)[O-])c1C#N
  • InChIKey: XXUZFRDUEGQHOV-UHFFFAOYSA-J
  • Mol. Mass: 513.49
  • ALogP: -0.08
  • ChEMBL Molecule:
    strontium ranelate  
More Chemistry

Pharmacology

Alternative names

3-(3-cyano-4-carboxymethyl-5-carboxy-2-thienyl)-3-azapentanedioic distrontium salt | bivalos | distrontium renelate | osseor | protelos | s12911 | s 12911 | s-12911 | s12911-0 | s12911-2 | s12911-5 | strontium ranelate

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Bone Diseases, Metabolic (Phase 4)

Compliance (Phase 4)

Hyperparathyroidism, Primary (Phase 4)

Osteoporosis (Phase 4)

Osteoporosis, Postmenopausal (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue